US DOJ slaps Merck with subpoena probing Temodar, PegIntron sales
This article was originally published in Scrip
Executive Summary
In a 8 August filing with the Securities and Exchange Commission, Merck disclosed it received a subpoena from the US Department of Justice (DOJ) seeking marketing and sales information for three drugs.